ARCHIVES

NCI To Use Technology Transfer Agreement To Privatize Journal In A Five-Year Deal

This article is from The Cancer Letter archive.

Vol. 21 No. 46 | December 1, 1995

Download PDF Visit The Full Archive

Related Articles

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

May 7, 2004

FOLFOX4 Improved PFS In Colorectal Cancer

April 25, 2008

FDA developing guidelines for oncology endpoints.

May 7, 2004

In Brief: Sundwall Leaves Hatch to head HRSA; Terry Joins Damon Biotech; Irlin On Hunger Strike

September 12, 1986

In Brief: Donald Metcalf Wins Bristol-Myers Award; NCI Starts Search for Biological Carcinogenesis AD

May 1, 1987

ACS Concludes That Laetrile Organization Is Insignificant

November 29, 1991